REVERSAL Trial

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

REVERSAL Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of REVERSAL Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on REVERSAL Trial

CDC on REVERSAL Trial

REVERSAL Trial in the news

Blogs on REVERSAL Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for REVERSAL Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

To compare the effects of pravastatin and atorvastatin on coronary artery plaque burden and progression by intensive lipid lowering.

Methods

Reversal of Atherosclerosis with Aggressive Lipid Lowering [REVERSAL] was a multicentered, randomized, double- blinded trial wherein 654 patients received the study drug. IVUS examinations were performed at baseline and after 18 months of treatment in 502 patients. Patients randomly received either 40 mg pravastatin or 80 mg of atorvastatin.

Results

The mean LDL-C levels reduced from 150 to 110 mg/dL in the pravastatin group and to 79 mg/dL in the atorvastatin. Percentage change in atheroma volume showed a significantly lower progression rate in the atorvastatin (intensive) group compared to the pravastatin group.

Conclusion

In patients with coronary artery disease, atorvastatin reduced progression of coronary atherosclerosis compared with pravastatin.[1]

References

  1. "Effect of intensive compared with moderate lipid-loweri... [JAMA. 2004] - PubMed - NCBI".